| Literature DB >> 29764868 |
Shanice Christie1,2,3, Vincy Chan1,3,4, Tatyana Mollayeva1,3,4, Angela Colantonio3,4,5.
Abstract
OBJECTIVE: Although a range of rehabilitation interventions have been applied to restore function after infectious encephalitis, there is a lack of literature summarising the benefits of these interventions. This systematic review aims to synthesise current scientific knowledge on outcome measures following rehabilitative interventions among children and adults with infectious encephalitis, with a specific focus on the influence of the age, sex, baseline status and intervention type. SEARCH STRATEGY: Five scholarly databases (MEDLINE, Embase, PsycINFO, CINAHL and Cochrane Central Register of Controlled Trials), three sources of grey literature (Google, Google Scholar and Grey Matters) and reference lists of included publications were systematically searched. Literature published before 15 December 2017 and focused on patients with infectious encephalitis in any rehabilitation setting were included. Quality assessment was completed using the Downs and Black rating scale.Entities:
Keywords: infectious encephalitis; intervention; non-traumatic brain injury; rehabilitation; rehabilitation outcome
Mesh:
Year: 2018 PMID: 29764868 PMCID: PMC5961616 DOI: 10.1136/bmjopen-2017-015928
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Our search yielded 12 737 citations, with an additional eight records identified from a grey literature database and two by hand-searching the reference lists of included studies. Figure 1 details our search and selection process. We selected reviews that, based on our inclusion criteria, had a full-text version available and examined a type of a rehabilitation intervention administered to patients with infectious encephalitis and excluded records that were (1) theoretical articles or review of treatment approaches; (2) studies describing pharmacological-based interventions not focused on rehabilitation as defined by the WHO; (3) studies not providing predata/postdata of intervention; and (4) studies not presenting results using patient outcome measure. We identified 20 studies that met both first and second screen criteria.
Summary of study characteristics by study design
| Author | Objective | Inclusion criteria/ | Sample size (N) | Infectious | Outcome | Statistical method | Scores | Other co-occurring interventions | |
| Preintervention | Post intervention | ||||||||
| Randomised crossover | |||||||||
| Emslie | To address rehab of memory and organisational problems with paging system. | IC: pts. with encephalitis from larger group of patients with non-progressive brain injury. | n=4. | HSV (n=3), mycoplasma encephalitis (n=1). | Task success (%) of messages and target behaviours. | OR test | T0 (BS) | T1 (7 weeks) | N/R |
| Cohort | |||||||||
| Moorthi | To describe outcome of pts. rehab. | IC: Dz. viral encephalitis, potential for function recovery, commitment by family for home discharge. | n=8. | HSV (n=2), James | FIM, FIM gain, FIM LOS efficiency, discharge destination. | N/R | T0 (BS) | T1 (5 weeks) | Acyclovir |
| Berner | To show benefit of geriatric rehab for patients with functional damage. | IC: independent function before illness; neurological disability secondary to illness; no cure of neurological damage 2 weeks after recovery from the acute disease; support from family; self-motivation. | n=5. | West Nile Virus (n=5). | Clinical evaluation, FIM, MMSE, CCT and MEAMS. | N/R | T0 (BS) | T1 (20–50 days) | N/R |
| Case series | |||||||||
| Tailor | Examined functional status of children with encephalitis. | IC: pts between April 1996 and December 2010 at an inpatient paediatric neurorehab unit. | n=13. | Anti-NMDA receptor (n=1), influenza (n=1), presumed mycoplasma (n=1), | WeeFIM | Descriptive statistics, paired t-tests, bivariate correlation analysis conducted on SPSS V.20.0. | T0 (BS) | T0 (11–85 days) | Unspecified antibiotics and antiviral agents. |
| Rao and Costa | Presents rehab programme of three pts. with HSV. | IC/EC: N/R. | n=3. | HSV. | Nine hole peg test, all ADLs, homemaking, ambulation, transfers, bowel and bladder, safety, behaviour, speech, comprehension, reading, math and writing. | N/R | T0 (BS) | T1 (2–10 weeks) | Acyclovir |
| Ponfick | To report five cases with meningoen-cephaloradiculomyelitis. | IC: diagnosis of tick-borne encephalitis. | n=5. | Tick-borne encephalitis. | FIM score at admission and discharge. | N/R | T0 (BS) | T1 (100–396 days) | Antibiotics, antivirals, acyclovir and intravenous immunoglobulin. |
| Case studies | |||||||||
| Andrewes | To show potential techniques for functional learning problems w/in workplace. | IC/EC: N/R. | n=1. | HSV. | WAIS–Revised, AVLT. | N/R | T0 (BS) | T1–T2 (5 and 24 months) | Acyclovir, penicillin and phenytoin. |
| Barikroo and Lam | To describe clinical and tx. observations of swallowing therapy technique. | IC/EC: N/R. | n=1. | N/R. | Performance of 3 oz water swallow test. | N/R | T0 (BS) | T1–T2 (3–6 months) | N/R |
| Brett | To report the effects of late community-based rehab. | IC/EC: N/R. | n=1. | HSV. | # of times incontinent per week. | P value test. | T0 (BS) | T1 (6 years) | Acyclo- |
| Katzmann and Mix | To describe tx. of patient w using behaviour modification techniques. | IC/EC: N/R. | n=1. | Viral encephalitis. | % of cues and assistance for activities of self-care routine. | N/R | T0 (BS) | T1 (12 weeks) | Anticonvulsant, antibiotics and antipsychotic medications. |
| Yamamoto | To describe problems in daily living of patient. | IC/EC: N/R. | n=1. | Limbic encephalitis. | TMT, PASAT, Miyake VRT, Benton VRT, KWCST, Rey’s figure test. | N/R | T0 (BS) | T1–T4 (14–26 months) | N/R |
| Miotto and Correo Miotto | Describes assessment and cognitive rehab of pt. | IC/EC: N/R. | n=1. | Viral meningo-encephalitis. | Mean number of daily episodes of failure to retrieve people/object names. | N/R | T0 (BS) | T1 (5 weeks) | N/R |
| Schinke and Olson | To design, implement and evaluate home-based remediation for pt. | IC/EC: N/R. | n=1. | Subacute sclerosing panencephalitis. | # of correct responses in math. | N/R | T0 (BS) | T1 (N/R) | N/R |
| Berry | Describes the use of SenseCam by patient w severe memory impairment. | IC/EC: N/R. | n=1. | Limbic encephalitis. | % of autobiographical events recalled using SenseCam. | χ2 analysis | T0 (BS) | T1–T3 (1–3 months) | N/R |
| Parkin | Examined errorless learning for restoring memory. | IC/EC: N/R. | n=1. | HSV. | Proportion of identified politician names. | Page’s L Statistic with session as the fixed factor and individual item scores as source of error variance. | T0 (BS) | T1 (5 months) | Acyclovir |
| McMillan | Described management of aggressive and hypersexual behaviour. | IC/EC: N/R. | n=1. | HSV. | # of violent behaviour and sexual disinhibition activities. | N/R | T0 (BS) | T1–T2 (10–32 weeks) | Intravenous acyclovir, warfarin, temazepam, carbamazepine, sulpride, lithium carbonate and intramuscular chlorpromazine. |
| Dewar and Gracey | To describe therapeutic intervention to address anxiety and changes in identity for pt. | IC/EC: N/R. | n=1. | HSV. | BDI, BAI | N/R | T0 (BS) | T1–T2 (30 weeks) | Acyclovir |
| Dewar and Wilson | To describe cognitive rehab programme to improve patient cognitive function. | IC/EC: N/R. | n=1. | Encephalitis lethargica. | WAIS 3, WMS 3 | N/R | T0 (BS) | T1 (8 weeks) | Unspecified steroids |
| Giles and Morgan | To present programme for personal hygiene behaviour. | IC/EC: N/R. | n=1. | HSV. | WAIS, Memory functions, WLMT, Rey-Osterrieth figure. | N/R | T0 (BS) | T1–T2 (2–16 weeks and3 months) | N/R |
| Miotto and Correa Miotto | Describes memory rehab of pt. w amnesia. | IC/EC: N/R. | n=1. | HSV. | WASI, FSIQ, WMS-III, RBMT, WRMT, HVLT, BNT, VOSPB. | Wilcoxon matched pairs test | T0 (BS) | T1 (7 months) | Acyclovir |
ADL, activities of daily living; AFIM, admission FIM; AVLT, Auditory Verbal Learning Test; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BNT, Boston Naming Test; BS, Baseline Score; CCT, Clock Completion Test; Del Rec, Delay Recall; DFIM, discharge FIM; DKEF, Delis-Kaplan Executive Function System; Dz., diagnosis; FIM: Functional Independence Measure; FOIS: Functional Oral Intake Scale; FSIQ, Full Scale Intelligence Quotient; GNT, Graded Naming Test; HSV, herpes simplex virus; HVLT, Hopkins Verbal Learning Test; IT, intervention; In/pt, inpatient; KWCST, Keio version of the Wisconsin Card Sorting Test; LOS, length of stay; MCST, Modified Card Sorting Test; MEAMS, Middlesex Elderly Assessment of Mental State; min: minimum; MMSE, Mini-Mental State Examination; NMDA, n-methyl-D-aspartate; N/R, not reported; Out/pt, outpatient; PAL, Paired Associate Learning; PASAT, Paced Auditory Serial Addition Test; pt, patient; RBMT, Rivermead Behavioural Memory Test; RCFT, Rey Complex Figure Test; RECOG, recognition; rehab, rehabilitation; SWAL-QOL, Swallow Quality of Life; TMT, Trial Making Test; Tx, treatment/therapy; VOSPB, Visual Object Space Perception Battery; VIQ, Verbal Intelligence Quotient; VRT, verbal reasoning test; WAIS, Wechsler Adult Intelligence Scale; WeeFIM, Functional Independence Measure for children; WIQ, WLMT, Wechsler Logical Memory Test; WMS: Wechsler Memory Scale; WRMT, Warrington Recognition Memory Test; w, with.
Downs and Black quality assessment of studies
| Moorthi | Emslie | Berner | Tailor | Rao | Ponfick | Andrewes | Barikroo | Brett | Katzmann | Yamamoto | Miotto | Schinke | Berry | Parkin | McMillan | Dewar | Dewar | Giles | Miotto | |
| Is the hypothesis/ | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Are the main outcomes to be measured clearly described in the Introduction or Methods? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Are the characteristics of the patients included in the study clearly described? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Are the interventions of interest clearly described? | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Are the distributions of principal confounders in each group of subjects clearly described? | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Are the main findings of the study clearly described? | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Does the study provide estimates of the random variability in the data for the main outcomes? | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Have all important adverse events that may be a consequence of the intervention been reported? | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Have the characteristics of patients lost to follow-up been described? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Have actual probability values been reported (eg, 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were the subjects asked to participate in the study representative of the entire population from which they were recruited? | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Were those subjects who were prepared to participate representative of the entire population from which they were recruited? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Were the staff, places and facilities where the patients were treated, representative of the treatment the majority of patients receive? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Was an attempt made to blind study subjects to the intervention they have received? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Was an attempt made to blind those measuring the main outcomes of the intervention? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| If any of the results of the study were based on ‘data dredging’, was this made clear? | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, is the time period between the intervention and outcome the same for cases and controls? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were the statistical tests used to assess the main outcomes appropriate? | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Was compliance with the intervention/s reliable? | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | *1 | 1 | 1 | 1 | 1 |
| Were the main outcome measures used accurate (valid and reliable)? | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case–control studies) recruited from the same population? | 0 | *1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case–control studies) recruited over the same period of time? | 0 | *1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were study subjects randomised to intervention groups? | 0 | *1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Was the randomised intervention assignment concealed from both patients and healthcare staff until recruitment was complete and irrevocable? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Were losses of patients to follow-up taken into account? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%? | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 14 | 12 | 12 | 13 | 11 | 9 | 11 | 7 | 7 | 9 | 12 | 10 | 12 | 11 | 9 | 13 | 12 | 11 | 10 |